Abstract
Leukotriene antagonists are a new class of anti-inflammatory drugs which have shown clinical efficacy in the management of asthma. However, their role in paediatric asthma is still unclear. In essence, while there are theoretical reasons as to why leukotriene antagonists would be of use in the management of childhood asthma, there is little clinical data on their use in this patient group.
Studies with leukotriene antagonists to date have been performed in children with chronic ‘undertreated’ asthma which, under current recommendations, should be treated with inhaled corticosteroids. Furthermore, the magnitude of effect of leukotriene antagonists on lung function (forced expiratory volume in one second of less than 5% better than placebo) and daily symptoms (0.23 puffs per day of B2 agonist less than placebo), while reaching statistical significance, is unlikely to be of clinical significance in children with chronic undertreated asthma. There is, however, good evidence for leukotriene antagonist use in exercise induced asthma in children.
We conclude that although leukotriene antagonists may play an important role in the management of childhood asthma in the future, particularly as corticosteroid sparing agents and in exercise induced asthma, clinical data in paediatric asthma is poor.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Busse W. Leukotrienes and inflammation. Am J Respir Crit Care Med 1998; 157 (6 Pt 2): S210–3
Horwitz R, Mcgill K, Busse W. The role of leukotriene modifiers in the treatment of asthma. Am J Respir Crit Care Med 1998; 157: 1363–71
Wenzel SE, Trudeau JB, Kaminsky DA, et al. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Respi Crit Care Med 1995; 152: 897–905
U.S. Preventive Services Task Force. Guide to clinical preventive services: second edition (1996) [online document]. Available from: http://www.ahcpr.gov/clinic/uspstfix.htm [Accessed 2000 Jun 27]
National Asthma Campaign. Asthma Management Handbook. Melbourne (Australia): National Asthma Campaign, 1998: 24
Israel E, Cohn J, Dube L, et al. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. JAMA 1996; 275(12): 931–6
Spector S, Miller C, Glass M. 13 week disease response study with zafirlukast in patents with mild to moderate asthma [abstract]. Am J Crit Care Med 1995; 151: A379
Nathan R, Glass M, Snader M. Effects of 13 weeks of treatment with ICI 20,219 (accolate) or cromolyn sodium in patients with mild to moderate asthma [abstract]. J Allergy Clin Immunol 1995; 95 Pt 2: 388
Leff J, Busse W, Pearlman D, et al. Montelukast, a leukotriene receptor antagonist for the treatment of mild asthma and exercise induced bronchoconstriction. N Engl J Med 1998; 339(3): 147–52
Reiss T, Hill J, Harman E, et al. Increased urinary excretion of LTE after exercise and attenuation of exercise induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax 1997; 53: 1030–5
Pearlman DS, Ostrom NK, Bronsky EA, et al. The leukotriene D4 receptor antagonist zafirlukast attenuates exercise induced bronchoconstriction in children. J Pediatr 1999; 134(3): 273–9
Edelman JM, Turpin JA, Bronsky EA, et al. Oral montelukast compared with inhaled salmeterol to prevent exercise induced bronchoconstriction: a randomised double blind trial. Ann Intern Med 2000; 132(2): 97–104
Knorr B, Matz J, Bernstein J, et al. Montelukast for chronic asthm a in 6 to14 year old children:a randomised double blind trial. JAMA 1998; 279(15): 1181–6
Reiss T, Chervinsky P, Dockhorn R, et al. Montelukast, a once daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter randomised double blind trial. Arch Intern Med 1998; 158: 1213–20
Reiss TF, Sorkness C, Stricker W, et al. Effects of montelukast, a potent cysteinyl leukotriene receptor antagonist on bronchodilation in asthmatic subjects treated with and without inhaled steroids. Thorax 1997; 52: 45–8
Spector S, Smith L, Glass M. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 antagonist in subjects with bronchial asthma. Am J Crit Care Med 1995; 150: 618–23
Busse W, Nelson H, Wolfe J, et al. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Clin Immunol 1999; 103: 1075–80
Tamaoki J, Kondo M, Sakai J, et al. Leukotriene antagonists prevent exacerbation of asthma during reduction of high dose inhaled steroid. Am J Respir Crit Care Med 1997; 155: 1235–8
Israel E, Rubin J, Kemp P, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild to moderate asthma. Ann Intern Med 1993; 119: 1059–66
Liu M, Dube L, Lancaster J, et al. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6 month randomised multicenter trial. J Allergy Clin Immunol 1996; 98: 859–71
O’Connor B, Godard P, Dube L, et al. The comparative effect of zileuton, a 5-lipoxygenase inhibitor plus low dose inhaled beclomethasone vs higher dose beclomethasone for asthma [abstract]. J Allergy Clin Immunol 1996; 97: 250A
Laviolette M, Malmstrom K, Lu S, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care 1999; 160(6): 1862–8
Josefson D. Asthma drug linked with Churg-Strauss syndrome. BMJ 1997; 315: 330
Green RL, Vayonis AG. Churg Strauss syndrome after zafirluk-ast in two patients not receiving systemic steroid treatment. Lancet 1999; 353: 725–6
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Selvadurai, H., Mellis, C. Antileukotriene Drugs in Childhood Asthma. Paediatr Drugs 2, 367–372 (2000). https://doi.org/10.2165/00128072-200002050-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128072-200002050-00004